Is the Durogesic DTrans transdermal patch bioequivalent to the Durogesic Reservoir transdermal patch?

Yes

Studies on the bioequivalence of the Durogesic DTrans and Reservoir transdermal patches have been carried by Janssen-Cilag following the EMEA guidelines. For information on these guidelines please click the links below:

• NOTES FOR GUIDANCE ON THE INVESTIGATION OF BIOAVAILABILITY AND BIOEQUIVALENCE - The European Agency for the Evaluation of Medicinal Products

• NOTE FOR GUIDANCE ON MODIFIED RELEASE ORAL TRANSDERMAL DOSAGE FORMS: SECTION II (PHARMACOKINETIC AND CLINICAL EVALUATION) - The European Agency for the Evaluation of Medicinal Products

A multi centred study by Freynhagen et al. (References) showed that patients with chronic pain could be switched from Durogesic reservoir patches to Durogesic DTrans patches without any loss of pain control or major adverse side effects.

For further information on the bioequivalent studies you can contact Janssen-Cilag Medical Information Service please click here for a direct link. Alternatively you can telephone

Janssen-Cilag Durogesic DTrans Link Line:

Tel No: 0800 716973 available 24 hours / 7 days per week:

previous page